


tectable change. It can be shown that the observed and [2,3] sigmatropic rate constants are related as follows, provided that $k_N \gg k_X$.⁶ $k_{2c2t}^{Se} \approx 2k_{2X}^{Se}$ and $k_{12}^{Se} \approx k_{1N}^{Se}$. Using the directly measured value for k_{12}^{Se} and the value for k_{2X}^{Se} obtained by extrapolating k_{2c2t}^{Se} to -80°C ($\Delta H^\ddagger = 24.9$ kcal/mol, $\Delta S^\ddagger = -7.0$ eu), it is possible to construct a partial free-energy diagram for the 1-Se/2-Se equilibration (Figure 1a). The free-energy difference of interest separating selenoxide and selenenate is $12.5 - \Delta\Delta G_{N/X}^\ddagger$ kcal/mol, where $\Delta\Delta G_{N/X}^\ddagger$ is the separation between the endo and exo transition states (i.e. k_N/k_X).

Since k_N/k_X cannot be directly measured for $Y = \text{Se}$, we decided to provide a partial answer by studying the sulfur analogue for which K_{eq} is directly measureable. The sulfenate ester 2-S was prepared from 2-methyl-3-buten-2-ol and *o*-nitrobenzenesulfenyl chloride at -50°C , and the rate of equilibration ($k_{12}^S + k_{21}^S$) with sulfoxide 1-S was measured at -29.7°C ($k_{12}^S + k_{21}^S = 0.000216\text{ s}^{-1}$, $K_{eq} = 23.9$). When the deuterium-labeled compound 2c-S^{7,9} was used, only a single diastereomer⁶ of 1-S was formed (>98%). Equilibration (k_{1a1b}^S) occurred at higher temperatures, and the rate was extrapolated to -29.7°C ($\Delta H^\ddagger = 21.7$ kcal/mol, $\Delta S^\ddagger = -1.6$ eu). From the three experimentally determined numbers k_{21}^S , k_{1a1b}^S , and K_{eq}^S , it was possible to calculate the [2,3] sigmatropic rate constants and construct the free-energy diagram (Figure 1b).

The most striking finding is the high value (275) of k_N^S/k_X^S ,⁶ corresponding to a $\Delta\Delta G_{N/X}^\ddagger$ of 2.7 kcal/mol. The k_N/k_X value represents the maximum possible asymmetry transfer from chiral sulfur to chiral carbon (if there is one) of the sulfenate. That such high values have been rarely achieved by using optically active sulfoxides for the synthesis of chiral allyl alcohols⁵ could be due in part to the inefficient cleavage of allyl sulfenates, but more likely reflect some peculiarity of the present system.^{5b,10}

Returning now to the original question of the selenenate-selenoxide equilibration we can estimate $\Delta\Delta G_{N/X}^\ddagger \approx 2$ kcal/mol, and thus $\Delta G_{1Se/2Se}^\circ \approx 11$ kcal/mol. Because of the long temperature extrapolation involved, we estimate a possible error of ± 2.5 kcal/mol. Since $\Delta G_{1S/2S}^\circ = -1.5$ kcal/mol, the equilibrium of eq 2 shifts by 12 kcal/mol on going from S to Se. The two principal contributors are the weaker C-Se bond strength compared to C-S and the smaller degree of multiple bonding in the dipolar Se-O vs. S-O bond. Some of the more dramatic differences between S and Se chemistry can be traced to the effect discussed here, (e.g., the fact that selenoxide syn eliminations are irreversible and much more rapid than those of sulfoxides¹¹).

The isomerization of selenoxide to selenenate can be facile even in situations where the double bond is part of an aromatic ring such as furan or phenanthrene. Even though the selenoxide 3 is



(5) (a) Bickart, P.; Carson, F. W.; Jacobus, J.; Miller, E. G.; Mislow, K. *J. Am. Chem. Soc.* **1968**, *90*, 4869. (b) Goldmann, S.; Hoffmann, R. W.; Maak, N.; Geueke, K.-J. *Chem. Ber.* **1980**, *113*, 831. (c) Rautenstrauch, V. *J. Chem. Soc., Chem. Commun.* **1970**, 526.

(6) We have no direct evidence on which is the lower to the two transition states (i.e., whether 1a-S or 1b-S is formed from 2c-S). From the results reported for the *cis*- and *trans*-2-butenyl¹⁵ and -octenyl¹⁶ sulfoxides, it is almost certainly the endo (1a-S). The most pertinent evidence is that 2c-S rearranges to the diastereomer of 1-S with D replacing the downfield H (CDCl₃) of the sulfoxide AB (X) pattern (δ_A 3.90, δ_B 3.61, $J_{AB} = 13.0$ Hz, $J_{AX} = 8.0$ Hz, $J_{BX} = 8.5$ Hz).

(7) Prepared from 1,1-dibutyl-2,3-dihydro-3,3-dimethyl-2-oxastannole⁸ by treatment with *n*-butyllithium/D₂O.

(8) Ensley, H. E.; Buescher, R. R.; Lee, K. *J. Org. Chem.* **1982**, *47*, 404.

(9) Isotope effects are small in sigmatropic rearrangements (e.g., for [3,3], $k_H/k_D = 0.97-1.1$ per D): Malojcic, R.; Humski, K.; Borcic, S.; Sunko, D. E. *Tetrahedron Lett.* **1969**, 2003; *J. Am. Chem. Soc.* **1970**, *92*, 6534.

(10) The X-ray structure of methyl *o*-nitrobenzenesulfenate shows a close NO₂-S approach. Hamilton, W. C.; LaPlaca, S. J. *J. Am. Chem. Soc.* **1964**, *86*, 2289.

(11) Reich, H. J.; Wollowitz, S.; Trend, J. E.; Chow, F.; Wendelborn, D. F. *J. Org. Chem.* **1978**, *43*, 1697.

the only species detected by NMR,¹² it is in rapid equilibrium with its selenenate isomer 4 since treatment with pyrrolidine gives alcohol 5 in a crude (NMR) yield of 87%.¹³ Purification by distillation is usually accompanied by some isomerization to furfuryl alcohol, as well as reversal to selenoxide 3. 9-Phenanthrenylmethyl phenyl selenoxide can similarly be converted to 9-methylene-10-hydroxy-9,10-dihydrophenanthrene.

Acknowledgment. We thank the National Institutes of Health, The National Science Foundation, and the donors of the Petroleum Research Fund, administered by the American Chemical Society, for support of this work.

Supplementary Material Available: Tables of observed and calculated rate constants used to construct Figure 1 (2 pages). Ordering information is given on any current masthead page.

(12) The loss of aromatic stabilization (15.8 and 17.3 kcal/mol for furan and phenanthrene) exceeds the predicted energy gain on conversion to selenenate. Gordon, A. J.; Ford, R. A. "The Chemist's Companion"; Wiley-Interscience: New York, 1972, p 131.

(13) 1-Alkenyl-1-cyclopropyl phenyl selenoxides behave similarly to selenoxide 3. Here the strain of the alkylidene cyclopropane makes the rearrangement endothermic. Halazy, S.; Krief, A. *Tetrahedron Lett.* **1981**, *22*, 2135.

Spectroscopic Observation of the Tautomer of 7-Deoxydaunomycinone from Elimination of Daunomamine from Daunomycin Hydroquinone¹

Don L. Kleyer and Tad H. Koch*

Department of Chemistry, University of Colorado
Boulder, Colorado 80309

Received December 15, 1982

Anaerobic reduction of daunomycin (1) in microsomes by NADPH^{2,3} and in solution by dithionite gives 7-deoxydaunomycinone (2).⁴ In vivo reductive elimination has been proposed to occur from the semiquinone (3) by some⁵⁻⁷ and from the hydroquinone (4) by others^{7,8} and to be at least in part responsible for covalent binding of the drug to DNA.⁶⁻⁸

Earlier we reported the efficient reduction of daunomycin to 7-deoxydaunomycinone by 6 and kinetic evidence that the reduction occurred possibly via hydride transfer.⁹ The kinetic measurements presumed no long-lived intermediates as suggested by prior electrochemical studies.¹⁰ This presumption has now been found to be inaccurate. Kinetics and spectroscopy establish that the reducing agent is 7¹¹ and reveal the elusive tautomer 5 of 7-deoxydaunomycinone.

A rigorously oxygen-degassed, methanol-*d* solution containing 1.79×10^{-4} M 1, 1.79×10^{-3} M 6, and 2.0×10^{-3} M trisma buffer (1:1 Tris/Tris-HCl) at $25.0 \pm 0.1^\circ\text{C}$ gave the spectral changes shown in Figure 1 during the time regime 10-130 s with scans every 10 s. The sequence of events was a fall in the absorption at 480 nm coupled with a short rise at 420 nm followed by a substantial rise at 380 and 608 nm. During the 380- and 608-nm band rise, the 420-nm band disappeared. Scans beyond 130 s

(1) Support: NCI, CA-24665, Developmental Therapeutics Program; University of Colorado, CCRW; 3M Co.

(2) Bachur, N. R.; Gordon, S. L.; Gee, M. V. *Mol. Pharmacol.* **1977**, *13*, 901.

(3) Bachur, N. R.; Gordon, S. L.; Gee, M. V. *Cancer Res.* **1978**, *38*, 1745.

(4) Smith, T. H.; Fujiwara, A. N.; Lee, W. W.; Wu, H. Y.; Henry, D. W. *J. Org. Chem.* **1977**, *42*, 3653.

(5) Bachur, N. R.; Gordon, S. L.; Gee, N. V.; Kon, H. *Proc. Natl. Acad. Sci. U.S.A.* **1979**, *76*, 954.

(6) Pan, S.-S.; Pederson, L.; Bachur, N. R. *Mol. Pharmacol.* **1981**, *19*, 184.



(7) Sinha, B. K.; Gregory, J. L. *Biochem. Pharmacol.* **1981**, *30*, 2626. Sinha, B. K. *Chem.-Biol. Interact.* **1980**, *30*, 67.

(8) Moore, H. W. *Science (Washington, D.C.)* **1977**, *197*, 527. Moore, H. W.; Czerniak, R. *Med. Res. Rev.* **1981**, *1*, 249.

(9) Barone, A. D.; Atkinson, R. F.; Wharry, D. L.; Koch, T. H. *J. Am. Chem. Soc.* **1981**, *103*, 1606.

(10) Rao, G. M.; Lown, J. W.; Plambeck, J. A. *J. Electrochem. Soc.* **1978**, *125*, 534.

(11) Koch, T. H.; Olesen, J. A.; DeNiro, J. *J. Am. Chem. Soc.* **1975**, *97*, 7285. Burns, J. M.; Wharry, D. L.; Koch, T. H. *Ibid.* **1981**, *103*, 849.


$$h_{m_1}/h_{m_2} = ([6]_{0_1}/[6]_{0_2})e^{k_1(t_{m_2}-t_{m_1})}$$
COc1ccc2c(c1)c3c(c2)c(O)c(O)c3C(=O)O

(1) For reviews see: (a) G. W. E. Plaut, C. M. Smith, and W. L. Alworth, *Ann. Rev. Biochem.*, **43**, 899 (1974); (b) G. M. Brown and J. M. Williamson, *Adv. Enzymol.*, **53**, 345 (1982).

(14) Lown, J. W.; Chen, H.-H. *Can. J. Chem.* **1981**, *59*, 3212.